MorphoSys AG (MOR) Receives €79.63 Average Target Price from Analysts

Shares of MorphoSys AG (ETR:MOR) have received an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is €79.63 ($98.30).

MOR has been the subject of several research reports. Independent Research set a €93.00 ($114.81) price target on shares of MorphoSys and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Goldman Sachs Group set a €72.00 ($88.89) price target on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Wednesday, November 8th. JPMorgan Chase & Co. set a €85.00 ($104.94) price target on shares of MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Berenberg Bank set a €85.00 ($104.94) price target on shares of MorphoSys and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Finally, Deutsche Bank set a €90.00 ($111.11) price target on shares of MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, November 8th.

Shares of MorphoSys (MOR) traded down €0.40 ($0.49) during mid-day trading on Friday, reaching €77.10 ($95.19). 132,438 shares of the company’s stock traded hands, compared to its average volume of 128,467. The firm has a market cap of $2,240.00 and a P/E ratio of -26.14. MorphoSys has a 52-week low of €47.10 ($58.15) and a 52-week high of €87.05 ($107.47).

ILLEGAL ACTIVITY WARNING: “MorphoSys AG (MOR) Receives €79.63 Average Target Price from Analysts” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/02/05/morphosys-ag-mor-receives-79-63-average-target-price-from-analysts.html.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply